Method, system and chip test paper for parallel detection on various cardiac markers

Abstract

The invention discloses a method, system and chip test paper for parallel detection on various cardiac markers. The chip test paper is used for detecting a part or all of the cardiac markers including cTNI (cardiac troponin I), cTNT (cardiac troponin T), MYO (myoglobin), CK-MB (isoenzymeof creatine kinase containing M and B subunits), BNP (B-type natriuretic peptide), CRP (C-reactive protein) and FABP (fatty acid-binding protein); the chip test paper comprises a first membrane and a second membrane; a ligand An of each marker is arranged on the first membrane, and a ligand Bn coupled with a signal marker is absorbed on the second membrane; and a detected material forming sandwich detection together with the ligands An and Bn is added from a sampling hole, then under the acting force of percolation or other factors, the detected material moves to be combined with the ligands An and Bn respectively to form a composite array of the first membrane-the ligand An-the detected material-the ligand Bn-the signal marker, which is fixed on the first membrane, the composite array and a capture fiber membrane are assembled simultaneously, and a detection hole is reserved. The method, the system and the chip test paper provided by the invention can be used for detecting the various cardiac markers simultaneously and quantitatively; moreover, the detection sensitivity can be improved, and the detection time is saved.

Description

technical field [0001] The invention belongs to the technical field of in vitro immune analysis, and relates to a parallel detection method for markers, in particular to a parallel detection method for multiple myocardial markers; the invention also relates to a parallel detection system for multiple myocardial markers; meanwhile, the present invention It also relates to a chip test paper for parallel detection of multiple myocardial markers. Background technique [0002] Cardiovascular diseases such as acute myocardial injury, chronic heart failure and atherosclerosis are common diseases that seriously endanger human health. Since the 1950s, the dynamic determination of the activities of some metabolic enzymes has been the gold standard for the diagnosis of acute myocardial infarction (acute myocardial infarction, AMI). However, these enzymes are not unique to the myocardium. They also exist in large quantities in other organs and muscles of the human body. In addition to ...

AI Technical Summary

Problems solved by technology

Colloidal gold label technology has played an important role in the field of rapid detection, which has won time for patient diagnosis, and is easy to use, which has won the favor of users; but due to the bottleneck of low detection sensitivity and inability to accurately quantify, it cannot give full play to its potential The demand for rapid diagnosis cannot compete with precise chemiluminescence and other technologies

Technology platforms such as chemiluminescence and time-resolved fluorescence have greatly improved the detection sensitivity, and with the assistance of a fully automatic detection system, the detection error and detection efficiency have been greatly improved; however, due to its relatively long detection time, and the instrument The equipment is relatively large and can only be carried out in the central laboratory. It still takes a long time from sample collection to the doctor getting the test results. At the same time, one test can only get the result of one marker, and it cannot measure multiple biological factors related to the patient at the same time. marker results, thus greatly limiting the full development of this technology platform

With the development of chip technology, technical platforms such as membrane chips, liquid chips, and glass chips have emerged one after another, which can achieve the purpose of synchronous testing of multiple biomarkers for the same sample, saving time and cost for patient testing, and saving samples at the same time. However, the platform technology still has cumbersome experimental reactions and operations that increase the detection error. At the same time, the equipment is relatively large, and it can only be carried out in the central laboratory. It also takes a long time from sample collection to doctors getting the experimental results. time limits its development

Limits further development in the field of immunoassays

Neither can meet the needs of the rapidly developing field of immunization

[0018] In view of this, due to the problems that the current detection method has a long detection time, rapid detection cannot be quantified, and the same detection can only obtain the result of one marker, there is an urgent need for a new detection method that can quickly and accurately detect and can Simultaneously detect the preparation of multiple myocardial markers, and it is also easy to carry and can be used anytime, anywhere

Images